Unstable Angina: Embolism Can Occur Prior to PCI Thrombus in proximal RCA Stain of muscle before injection begins: TIMI Myocardial perfusion grade 1 CM.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy Non STE ACS
Advertisements

Risk stratification and medical management of NSTE-ACS (UA/NSTEMI )
Acute Coronary Syndromes. Acute Coronary Syndrome Definition: a constellation of symptoms related to obstruction of coronary arteries with chest pain.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Intracoronary Serotonin and Endothelin Release After PCI / Stenting Taylor AJ. Am Heart J Aug;148(2): e10 Leosco et al, AJC 1999;84:
Anterior Depressions Angiographic and Clinical Outcomes Among Patients with Acute Coronary Syndromes Presenting with Anterior ST-Segment Depressions C.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
GUSTO I GUSTO I Median Time (hrs) Between Symptom Onset and Treatment GUSTO III GUSTO III InTIME II InTIME II ASSENT.
Acute Coronary Syndromes
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
1 DIAGNOSTICS OF Acute Coronary Syndromes At the end of this self study the participant will: Verbalize meanings of specific ECG changes: –ST Elevation.
Ischemic heart disease Basic Science 3/15/06. All of the following concerning coronary artery anatomy are correct except: The left main coronary artery.
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
VULNERABLE PLAQUES: Pertinent doubts and solutions in interventional cardiology EuroPCR Paris, 16 May 2006.
Ischemic Heart Disease CVS3 Hisham Alkhalidi. Ischemic Heart Disease A group of related syndromes resulting from myocardial ischemia.
Intracoronary Eptifibatide Bolus Administration During Percutaneous Coronary Revascularization for Acute Coronary Syndromes With Evaluation of Platelet.
1 Pathophysiology & Clinical Presentations Acute Coronary Syndromes.
Is PCI necessary for AMI related artery with TIMI 3 flow ? Donghoon Choi Yonsei Cardiovascular Center Yonsei University College of Medicine.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Beyond TIMI 3 Flow CTFC < 14 CTFC > % (n=41) (n = 18/640) (n =35/563) 2.8% p= “TIMI 4” Flow TIMI 3 Flow 14 < CTFC < % % Risk of In Hospital.
Myocardial Infarction  MI = heart attack  Defined as necrosis of heart muscle resulting from ischemia.  A very significant cause of death worldwide.
ACUTE CORONARY SYNDROMES Part I. Definition Acute coronary syndrome (ACS) describes a spectrum of clinical conditions ranging from ST segment elevation.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Antiplatelet Interventions in Acute Coronary Syndromes.
LESSON 1 LESSON 1 Establishment of:
Is the Decision-Making after Failure of CTO Angioplasty Same? Infarct Related CTO or Non- Infarct Related CTO (Continue the Procedure in Other Vessel or.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Ischemic Heart Disease CVS3 Hisham Alkhalidi. Ischemic Heart Disease A group of related syndromes resulting from myocardial ischemia.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Myocardial Infarction
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
Myocardial Infarction (MI) Prepared by Miss Fatima Hirzallah RNS, MSN,CNS.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Acute Coronary Syndrome
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Ischemic Heart Disease
Fractional Flow Reserve Workshop
Dr. Harvey White on behalf of the ACUITY investigators
No Reflow Reflow P value Arrhythmia 40% 18% Lecture Notes
Section A: Introduction
European Heart Association Journal 2007 April
European Society of Cardiology 2003
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
Published in the European Heart Journal
Impact of Platelet Reactivity Following Clopidogrel Administration
In STEMI Complete Reperfusion (TFG 3, TMPG 3, ST Res  70%) is Associated with a Greater Percent of Receptors Occupied by Integrilin 52.0% % Pts With Complete.
Myocardial Staining (TMPG 1)  Post-Stent in AMI
52.0% Complete Resolution TFG 3 TMPG 3 ST Resolution  70% p=0.006
Secondary Efficacy Endpoints
TIMI Myocardial Perfusion (TMP) Grades Dye strongly persistent
TAXUS – Myonecrosis and sidebranch patency concerns are short-term issues with no long-term consequences, and the benefits are undeniable Jeffrey J. Popma,
on behalf of the ACUITY investigators
Dye strongly persistent
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
A New Angiographic Risk Score in Facilitated PCI
Dye strongly persistent
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
MRI Hyperenhancement is Associated with Myonecrosis Following PCI
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
GUSTO 1 Trial 41,000 patients enrolled, landmark study
ESPRIT INTEGRITI TACTICS Rate of Increase in DSA
Cardiovascular Epidemiology and Epidemiological Modelling
Dye strongly persistent
Presentation transcript:

Unstable Angina: Embolism Can Occur Prior to PCI Thrombus in proximal RCA Stain of muscle before injection begins: TIMI Myocardial perfusion grade 1 CM Gibson 2002

T-wave inversion ST  ST  GUSTO 2B: ST Depression A High-Risk Patient Population P  CM Gibson 2002

Unstable Angina: Platelet Plugging of the Capillaries From: Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death Davies MJ, Circulation 1986 “The results support the view that platelet aggregates in the myocardium represent an embolic phenomenon and are a potential cause of unstable angina. The association of myocardial necrosis with such emboli could precipitate sudden death from ventricular fibrillation.”

ST  ST  UA / Non STEMI versus STEMI Mechanisms of Long Term Outcomes Necrosis by closed Muscle Necrosis by closed Muscle Necrosis by closed Artery Necrosis by closed Artery Arrhythmias CHF Arrhythmias CHF Death CM Gibson 2002

Correlation Between Elevated Cardiac Enzymes at Presentation and Long-term Mortality + Cardiac Troponin T at Baseline (n=559) 14.1% 4.5% – Cardiac Troponin T at Baseline (n=474) % mortality at 1 year Newby LK et al. Circulation. 1998; 98: P<0.0001

Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days   % % % % % % % % % % % %

Audience Poll What is a powerful angiographic predictor of the patient’s troponin status? Circulation 2002;106:

Even when epicardial TIMI flow grade and the presence of thrombus were adjusted for, the presence of a closed microvasculature was independently associated with tnT elevation in a multivariate model (O.R. 1.79, p=0.017). Circulation 2002;106: Answer:

Tissue Perfusion Predicts Troponin Release % Stenosis % Vessel Occlusion % Normal TMPG 3 % Thrombus tnT + tnT - P=0.021 P= P=0.03 P=0.007 Even when epicardial TIMI flow grade and the presence of thrombus were adjusted for, the presence of a closed microvasculature was independently associated with tnT elevation in a multivariate model (O.R. 1.79, p=0.017). Circulation 2002;106:

Event Free Survival is Associated with Tissue Level Perfusion in UA / Non Q Wave MI: TACTICS – TIMI 18 Circulation 2002;106: Log rank p=0.026 Days Event Free Survival TMPG 0/1 Pre & Post PCI TMPG 0/1 Pre & Post PCI TMPG 2/3 Pre or Post-PCI

TMPG and Maximum CK-MB 24 Hours Post-stent Maximum CK-MB >2x ULN (%) 41.2% p = /2414/34 4.2% All Patients Have TIMI 3 Flow at Completion of Stenting Gibson, Am Heart J 2002

The Time Dependent Open Artery and Open Microvascular Hypothesis Plaque rupture/erosion/fissure Platelet thrombus EmbolizationEmbolization Time Dependent Necrosis TIMI 2 Flow VasoconstrictionVasoconstriction Impaired tissue level perfusion Arrhythmias / CHF EdemaEdema InflammationInflammation TIMI 0 Flow Non – Occlusive UA / NSTEMI Non – Occlusive UA / NSTEMI Occlusive STEMI Occlusive STEMI + Troponin / CK Death CM Gibson 2002 GP 2b3a Antithrombin + GP 2b3a GP 2b3a Antithrombin + GP 2b3a

Conclusions:Conclusions: The source of Tn and CK is the muscle Tn positive: Poorer muscle perfusion before PCI 1 CK positive: Poorer muscle perfusion post PCI 2 Poorer TMPG before PCI: worse outcomes at 6 months in TACTICS 1 Poorer TMPF after PCI: worse outcomes at one year in ESPRIT 2 The source of Tn and CK is the muscle Tn positive: Poorer muscle perfusion before PCI 1 CK positive: Poorer muscle perfusion post PCI 2 Poorer TMPG before PCI: worse outcomes at 6 months in TACTICS 1 Poorer TMPF after PCI: worse outcomes at one year in ESPRIT 2 2. Gibson, Am Heart J Circulation 2002;106: